What is Progyny's stock-based comp?

Progyny (PGNY) reported stock-based comp of $19.72M in Q1 2026.

How has Progyny's stock-based comp changed year-over-year?

Progyny's stock-based comp decreased by 39.3% year-over-year, from $32.51M to $19.72M.

What is the long-term trend for Progyny's stock-based comp?

Over 4 years (2021 to 2025), Progyny's stock-based comp has grown at a 40.6% compound annual growth rate (CAGR), from $33.71M to $131.87M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Progyny PGNY Stock-Based Comp

Stock-Based Comp at other companies

CVS HealthCVS

$266M+111%

UnitedHealth GroupUNH

$348M-7.2%

Natera, Inc.NTRA

$95.11M+22.2%

OrganonOGN

$19M-20.8%

BillionToOne, Inc. BLLN

$6.51M+174%

Privia Health Group, Inc.PRVA

$21.92M+23.2%

Other financials

Income statement

See full

Revenue$328.5M+1.4%

Gross profit$83.1M+9.6%

Operating income$35.4M+46.4%

Net income$24.2M+60.9%

EPS (diluted)$0.29+70.6%

Balance sheet

See full

Cash & equivalents$131.6M+20.5%

Total debt$27.3M-5.6%

Total equity$439.3M-6.0%

Total assets$698.3M-4.4%

Cash flow

See full

Operating cash flow$45.9M-7.7%

CapEx$6.3M+123%

Free cash flow$39.6M-15.7%

Valuation

See full

Market cap$2.11B-27.1%

Profitability

See full

Gross margin24.1%+2.1pp

Operating margin7.5%+1.4pp

Net margin5.2%+0.9pp

FCF margin14.3%-1.9pp

Returns & leverage

See full

Return on equity14.9%+4.8pp

Debt / equity0.1×0.0×

Current ratio2.1×-0.3×

Where this comes from

Reported directly by Progyny in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Progyny’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Progyny's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Progyny's stock-based comp?: Progyny (PGNY) reported stock-based comp of $19.72M in Q1 2026.
How has Progyny's stock-based comp changed year-over-year?: Progyny's stock-based comp decreased by 39.3% year-over-year, from $32.51M to $19.72M.
What is the long-term trend for Progyny's stock-based comp?: Over 4 years (2021 to 2025), Progyny's stock-based comp has grown at a 40.6% compound annual growth rate (CAGR), from $33.71M to $131.87M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.